Primer: RemeGen (9995 HK) - Aug 2026
RemeGen has successfully transitioned from a pre-revenue R&D company to a commercial-stage biopharmaceutical firm, achieving profitability...
111 Views
RemeGen (9995 HK): Telitacicept Approval For More Indications A Positive
​RemeGen received marketing approval for IgA nephropathy and Sjögren’s Disease. These approvals of telitacicept will help boost revenue...
128 Views
Key Takeaways from WCLC 2026: Akeso/SMMT, Hansoh/GSK, MediLink/Roche, RemeGen/AbbVie...
For WCLC 2026 (World Conference on Lung Cancer), we summarise key updates for drugs from Akeso/SMMT, Hansoh/GSK, MediLink/Roche, RemeGen/AbbVie,...
106 Views
BUY/SELL/HOLD: Hong Kong Market Update (August 2026)
The Hong Kong market continues to show gains on the back of a strong July. The standout sectors this month include materials and healthcare.
104 Views
Remegen (9995 HK): New Licensing Deal With AbbVie Brings $650M Upfront Cash
Remegen inked an exclusive outlicensing deal with AbbVie for RC148, an investigational PD-1/ VEGF bispecific antibody drug candidate for an upfront...
272 Views